# Bexagliflozin Efficacy and Safety Trial

Study · id `cardio:ct-nct02558296` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02558296](<https://clinicaltrials.gov/study/NCT02558296>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02558296

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1700 participants.

## Technical summary

Registry record NCT02558296. Randomized; quadruple masking; primary purpose treatment. Start 2015-10 (actual); primary completion 2018-08 (actual). Results posted on 2021-07-07.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1700 participants (enrolled count; ClinicalTrials.gov record NCT02558296, source copy `cardio:ctgov-nct02558296-2021-07-14`, retrieved 2026-10-26)
- Started: 2015-10 (actual) (ClinicalTrials.gov record NCT02558296, source copy `cardio:ctgov-nct02558296-2021-07-14`, retrieved 2026-10-26)
- Primary completion: 2018-08 (actual) (ClinicalTrials.gov record NCT02558296, source copy `cardio:ctgov-nct02558296-2021-07-14`, retrieved 2026-10-26)
- Completion: 2019-10-23 (actual) (ClinicalTrials.gov record NCT02558296, source copy `cardio:ctgov-nct02558296-2021-07-14`, retrieved 2026-10-26)
- Results first posted: 2021-07-07 (ClinicalTrials.gov record NCT02558296, source copy `cardio:ctgov-nct02558296-2021-07-14`, retrieved 2026-10-26)
- Countries: United States; Canada; Czechia; Denmark; Mexico; Netherlands; Poland; Russia; South Korea; Taiwan (ClinicalTrials.gov record NCT02558296, source copy `cardio:ctgov-nct02558296-2021-07-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02558296-2021-07-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Bexagliflozin Efficacy and Safety Trial
- Acronym: BEST
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Bexagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Theracos
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Theracos (`cardio:org-theracos`)

## Provenance

Content hash: f47d796ff2c6144a1ceaf28484e95dcac2a1dae69ff9aad9989fc6d6feb67129
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
